Pharmaceutical giant Moderna has commenced a study to evaluate the effectiveness of its COVID vaccine in children under the age of 12, including infants as young as six months. The clinical trial aims to enroll 6,750 healthy children across the United States and Canada.
“There is significant interest in understanding the implications of vaccinating children,” states Dr. Emily Carter, the medical director of a vaccine clinic at a major university, in an interview with a leading publication.
Participants in the trial will receive two doses of the vaccine, spaced 28 days apart. Children aged two to 12 will be administered either 50 or 100 micrograms, while infants under two may receive doses of 25, 50, or 100 micrograms. This initiative offers hope to parents eager for their children to gain immunity as millions of adults have already been vaccinated. Health experts, including Dr. Anthony Fauci, emphasize the importance of vaccinating children for achieving herd immunity, and the American Academy of Pediatrics has advocated for expanding vaccine trials to include younger populations.
In another ongoing trial, Moderna is studying the vaccine in 3,000 adolescents aged 12 to 17, with results anticipated by summer. If proven safe and effective, the vaccine must still gain authorization for use in younger age groups before distribution can begin. Previously, in December 2020, the FDA approved the Pfizer-BioNTech vaccine for individuals aged 16 and 17, while Moderna’s vaccine is currently only authorized for adults aged 18 and older.
During the trials, the first group of children will receive the lowest doses, with close monitoring for any adverse reactions before administering higher doses to subsequent participants. Following this analysis, children will receive their doses based on the findings. After vaccination, the children will be monitored for a year to assess side effects and measure antibody responses, which will indicate levels of protection offered by the vaccine.
Estimates suggest that older children could be vaccinated as early as this fall, while younger children may have to wait until late 2021 or early 2022. This study marks a significant milestone, launching a year after the first adult received a dose of the Moderna vaccine during initial trials in March.
If you’re interested in more information on related topics, check out this other blog post here. For further insights on this subject, refer to this authority on the topic. Additionally, if you’re looking for excellent resources about pregnancy and home insemination, this site is highly recommended.
Search Queries:
- home insemination kits
- self insemination techniques
- IVF options
- how to get pregnant at home
- home insemination procedures
In summary, Moderna is advancing its research on COVID vaccinations for young children, aiming to provide critical protection for this vulnerable age group. With ongoing trials and expert insights, the hope is to extend vaccine availability to children soon.